Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · March 29, 2023

Association Between Treatment Intensity and Measurable Residual Disease and Outcomes in Patients With AML

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity
Blood Adv 2023 Mar 08;[EPub Ahead of Print], A Bazinet, TM Kadia, NJ Short, G Borthakur, SA Wang, W Wang, S Loghavi, JL Jorgensen, KP Patel, CD DiNardo, NG Daver, Y Alvarado, FG Haddad, SR Pierce, GM Nogueras Gonzalez, A Maiti, K Sasaki, M Yilmaz, PA Thompson, WG Wierda, G Garcia-Manero, M Andreeff, EJ Jabbour, MY Konopleva, X Huang, HM Kantarjian, F Ravandi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading